Skip to main content
. 2018 Mar 22;20(5):432–442. doi: 10.1016/j.neo.2018.02.004

Figure 1.

Figure 1

Dacomitinib inhibits EGFR activity and downstream signaling in glioblastoma, medulloblastoma and pineoblastoma cells. Immunoblot analyses of (A) U87.GFP.Luc2 and U87.vIII.Luc2 (C) GBM6 (D) Daoy.Luc2 and (E) 452.Luc2 cells using the indicated antibodies. Cells were treated with increasing concentrations of dacomitinib and protein was harvested as described in the methods. (B) U87MG glioblastoma cells were transduced with a retrovirus to drive expression of EGFRvIII, GFP and pacLuc2. Cells were cultured in the absence (DMSO) or presence of dacomitinib and phosphorylation of EGFRvIII was determined by immunofluorescence for phosphorylated EGFR (Y1173) (phospho-EGFRvIII, orange). Staining for GFP (green) confirms cells in the dacomitinib treated sample were successfully transduced. Nuclei were counterstained with DAPI (blue). Scale bar applies to all images.